Protalix BioTherapeutics (PLX) EBITDA Margin Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,658.00 |
| Dec 31, 2025 | -1,400.00 |
| Sep 30, 2025 | 3,795.00 |
| Jun 30, 2025 | 3,021.00 |
| Mar 31, 2025 | -5,925.00 |
| Dec 31, 2024 | 2,567.00 |
| Sep 30, 2024 | 3,489.00 |
| Jun 30, 2024 | 3,203.00 |
| Mar 31, 2024 | -7,655.00 |
| Dec 31, 2023 | 15,556.00 |
| Sep 30, 2023 | 54,601.00 |
| Jun 30, 2023 | 39,441.00 |
| Mar 31, 2023 | 8,749.00 |
| Dec 31, 2022 | 61,932.00 |
| Sep 30, 2022 | 8,114.00 |
| Jun 30, 2022 | 10,683.00 |
| Mar 31, 2022 | 37,507.00 |
| Dec 31, 2021 | 35,228.00 |
| Sep 30, 2021 | 12,672.00 |
| Jun 30, 2021 | 41,877.00 |
| Mar 31, 2021 | 112,544.00 |
| Sep 30, 2020 | 35,047.00 |
| Jun 30, 2020 | 39,754.00 |
| Mar 31, 2020 | 33,988.00 |
| Mar 31, 2019 | 4,358.00 |
| Dec 31, 2018 | -41,974.00 |
| Sep 30, 2018 | -31,710.00 |
| Jun 30, 2018 | -3,169.00 |
| Mar 31, 2018 | 1,100.00 |
| Dec 31, 2017 | 33,516.00 |
| Sep 30, 2017 | 4,613.00 |
| Jun 30, 2017 | -20,678.00 |
| Mar 31, 2017 | -22,961.00 |
| Dec 31, 2016 | -4,401.00 |
| Sep 30, 2016 | 63,211.00 |
| Jun 30, 2016 | 125,379.00 |
| Mar 31, 2016 | -103,613.00 |
| Sep 30, 2015 | -28,495.00 |
| Jun 30, 2015 | 47,161.00 |